Abstract
Pulmonary hypertension (PH) affects 1% of people worldwide. Changes in the pulmonary vasculature, obstructive lesions in the pulmonary arteries, and an increase in pulmonary artery pressure are the hallmarks of PH, a progressive and deadly cardiovascular illness. These modifications result in a rise in right ventricular afterload, which frequently causes unfavorable right ventricular remodeling, right ventricular dysfunction and, in the end, mortality. One of the more severe and well-researched types of PH is pulmonary arterial hypertension (PAH), which is treatable with medication. The mechanisms involved in the regulation of pulmonary vascular tone and proliferation are the focus of PAH as well as some other forms of PH. The main characteristics of PAH (group 1) are discussed in this article, along with new and existing treatment options for the condition.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
